Ascendent Capital Partners Mergers and Acquisitions Summary

Private Equity Profile

In the last 3 years, Ascendent Capital Partners has acquired 1 company.

Ascendent Capital Partners’ most common sector for investment is life science (100%). The Firm’s most common investment types include going private (100%). In total, Ascendent Capital Partners has invested in 1 US state. Its largest (disclosed) acquisition occurred in 2017 when it acquired SciClone Pharmaceuticals for $605M.

Join Mergr to view Ascendent Capital Partners’ full profile and discover more middle-market private equity firms just like it.

M&A Summary

  • M&A Total Activity1
    • M&A Buy Activity1
  • Total Sectors Invested 1
  • Total Countries Invested 1
  • M&A Advisors 2

Ascendent Capital Partners

Suite 3501, 35/F, Jardine House | 1 Connaught Place,
Central,
China
+852 2165 9000
www.ascendentcp.com

Ascendent Capital Partners is a private equity firm focused on acquiring and investing in China-related companies. The Firm looks to leverage its network and experience when working with and helping companies grow. Ascendant Capital Partners has offices in Shanghai and Hong Kong.


Investment Criteria

Sectors of Interest: Education, Food, Healthcare Services, Internet Software and Services, Life Science, Packaging

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital

Geographic Preferences: Asia/Pacific

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '15 '16 '17 '18 '19 '20 T
Buy (0.2/yr) # - - 1 - - - 1
vol $605M $605M
Sell (0.0/yr) # - - - - - - 0
  1

Most Recent M&A

Company Date Value Type
SciClone Pharmaceuticals, Inc. 2017-06-08 605M USD Going Private
Foster City, California · www.sciclone.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 1 (100%) 605M (100%) 1 (100%) 605M (100%)
Total 1 $605M 1 $605M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 1 (100%) 605M (100%) 1 (100%) 605M (100%)
  California 1 (100%) 605M (100%) 1 (100%) 605M (100%)
Total 1 $605M 1 $605M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Going Private 1 (100%) 605M (100%) 1 (100%) 605M (100%)
Total 1 $605M 1 $605M

Top M&A Advisors

Financial Deals
Morgan Stanley
 1
Legal Deals
Skadden, Arps, Slate, Meagher & Flom LLP
 1

Deal Values

buy # Total
$100M to $1B 1 $605M
TOTAL $605M
Largest SciClone Pharmaceuticals, Inc.
$605M (2017-06-08)

Investor Summary

Size

Middle-Market

Specialist/Generalist

Generalist

Leadership

Liang Meng

Co-Founder & Managing Partner

Stone Shi

Partner

John Wang

Partner

Jeffrey Chen

Partner

 Subscribe to unlock this and 152,039
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.9K Private Equity Firms
  • 140K M&A Transactions
  • 148K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.1K M&A Advisors
    (Investment Banks and Law Firms)
  • 41K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal